ADXN (Addex Therapeutics) E10: $-50.52 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADXN Addex Therapeutics Ltd ADXN
26 GF Score
Price $3.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics E10?

Addex Therapeutics ADXN +1.37% 26 E10 is $-50.52 as of Mar. 2026. GuruFocus rates ADXN with a GF Score™ of 26/100 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Addex Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $-1.524. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-50.52 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-09-09), Addex Therapeutics's current stock price is $3.66. Addex Therapeutics's E10 for the quarter that ended in Mar. 2026 was $-50.52. Addex Therapeutics's Shiller PE Ratio of today is .


Addex Therapeutics  (NAS:ADXN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Addex Therapeutics E10 Related Terms


Addex Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics E10 Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -57.87 -44.06 -44.59

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.40 -53.32 -48.00 -44.59 -50.52

ADXN vs VRTX, REGN, MRNA: E10 Comparison

For the Biotechnology subindustry, Addex Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Addex Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Shiller PE Ratio falls into.


ADXN
26GF Score
Addex Therapeutics Ltd ADXN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Addex Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Addex Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.524/108.0600*108.0600
=-1.524

Current CPI (Mar. 2026) = 108.0600.

Addex Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 0.000 101.036 0.000
201406 0.000 101.517 0.000
201412 0.000 100.704 0.000
201506 0.000 100.464 0.000
201512 0.000 99.386 0.000
201606 0.000 100.088 0.000
201612 0.000 99.380 0.000
201706 0.000 100.285 0.000
201712 0.000 100.213 0.000
201806 0.000 101.435 0.000
201812 0.000 100.906 0.000
201903 -14.393 101.571 -15.313
201906 -20.648 102.044 -21.865
201909 -16.959 101.396 -18.074
201912 -17.097 101.063 -18.281
202003 -20.015 101.048 -21.404
202006 -15.137 100.743 -16.236
202009 -15.739 100.585 -16.909
202012 -10.806 100.241 -11.649
202103 -10.325 100.800 -11.069
202106 -18.506 101.352 -19.731
202109 -14.304 101.533 -15.224
202112 -16.938 101.776 -17.984
202203 -19.367 103.205 -20.278
202206 -23.500 104.783 -24.235
202209 -11.096 104.835 -11.437
202212 -6.098 104.666 -6.296
202303 -5.186 106.245 -5.275
202306 -5.331 106.576 -5.405
202309 -4.002 106.570 -4.058
202312 -4.163 106.461 -4.226
202403 -4.051 107.355 -4.078
202406 17.454 107.991 17.465
202409 -2.833 107.468 -2.849
202412 -1.346 107.128 -1.358
202503 -1.358 107.722 -1.362
202506 -2.951 108.075 -2.951
202509 -1.507 107.710 -1.512
202512 -1.506 107.200 -1.518
202603 -1.524 108.060 -1.524

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-50.52 mean?
Addex Therapeutics (ADXN) has a E10 of $-50.52 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' E10 too high?
Addex Therapeutics' current E10 is $-50.52. Overall, Addex Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' E10 compare to VRTX and REGN?
Addex Therapeutics' E10 of $-50.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current E10 is $-50.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (ADXN) is currently considered Significantly Overvalued. The current E10 is $-50.52. Addex Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Addex Therapeutics (ADXN), the current E10 is $-50.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
26GF Score

Get the complete analysis for ADXN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price